Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

Dongiovanni, Vincenzo; Buffoni, L; Berruti, Alfredo; Dongiovanni, Diego; Grillo, R.; Barone, C.; Addeo, Alfredo; Fissore, C.; Bertetto, Oscar

doi:10.1007/s00280-005-0157-6

Cited by 11 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, a number of regimens have demonstrated activity in second-line settings, with treatment outcomes strongly depending on type of response to first-line therapy, treatment-free interval, and performance status [28,29]. However, the only second-line treatment for SCLC approved by the US Food and Drug Administration (FDA) is topotecan [30,31].…”

Section: Discussionmentioning

confidence: 99%

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Eisen

Thatcher

Leyvraz³

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Eisen

Thatcher

Leyvraz³

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

“…Our study began in 2005, and a similar study's report was published in 2006. They showed that weekly paclitaxel and gemcitabine treatment were moderately active in SCLC patients pretreated with platinum and etoposide [ 19 ]. Paclitaxel (80 mg/m 2 ) was given on days 1, 8, and 15, and gemcitabine (1,000 mg/m 2 ) was given on days 1 and 8 every 3 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…However, G4 neutropenia was common (47% vs. 64.2%), and diarrhea of all grades was observed (35.9% vs. 19.9%). A study of second-line weekly paclitaxel and gemcitabine showed G3-4 asthenia in 13% of patients [ 19 ]. The average relative dose intensity was 72% for paclitaxel and 83% for gemcitabine.…”

Section: Discussionmentioning

confidence: 99%

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

PurposePaclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen.Materials and MethodsEligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression.ResultsThirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia.ConclusionSecond-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.

show abstract

“…Recently Dongiovanni et al [29] evaluated the efficacy and toxicity of paclitaxel and gemcitabine in combination for treatment of relapsed SCLC. The treatment regimen consisted of paclitaxel, 80 mg/m 2 on days 1, 8, and 15, and gemcitabine, 1000 mg/m 2 on days 1 and 8 every 3 weeks.…”

Section: Paclitaxelmentioning

confidence: 99%

Second-line treatment of small-cell lung cancer

MacCallum¹,

Gillenwater

2006

Curr Oncol Rep

View full text Add to dashboard Cite

Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population. The only second-line treatment for small-cell lung cancer approved by the US Food and Drug Administration is topotecan. Other agents have been investigated and have shown modest efficacy. These include vinorelbine, irinotecan, etoposide, paclitaxel, and gemcitabine. Novel "targeted therapies" have shown disappointing results in this disease. Much of the recent work has focused on investigating alternative dosing and scheduling of topotecan. Combination therapies have also been investigated, and some have been shown to increase activity over single agents, but toxicity and quality of life variables are imperative in the treatment of this patient population.

show abstract

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

Abstract: To conclude, this weekly schedule of paclitaxel and gemcitabine was found to have moderate activity in platinum-etoposide pretreated SCLC patients and a favorable toxicity profile.

Cited by 11 publications

References 27 publications

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

Second-line treatment of small-cell lung cancer

Contact Info

Product

Resources

About